MURGY vs RGA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

MURGY is the larger of the two ($79.89B market cap): the incumbent the market prices for continued execution (11.03x forward earnings, beta 0.27). RGA is the smaller challenger ($17.53B), cheaper on forward earnings (8.77x): more room to run, but more to prove. If you believe MURGY earns its premium (11.03x forward earnings, so the market expects more from it), MURGY fits. If you believe in paying less for profit, RGA fits at 8.77x.

MURGY vs RGA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricMURGYRGAWhat it tells you
Market cap$79.89B$17.53BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E11.038.77Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E10.2410.44Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.270.40Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range73% of range92% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.131.51How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: RGA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how MURGY and RGA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MURGY and RGA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MURGY and RGA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Munich Re (MURGY) do?

Munchener Ruckversicherungs-Gesellschaft, known as Munich Re, is a Munich-based insurance group founded in 1880. Its core business is reinsurance: it insures other insurance companies against large losses from natural catastrophes, big commercial risks, liability claims and life and health exposures, so primary insurers can write more policies without carrying all the tail risk themselves. Reinsurance produces most of the group's profit. The second leg is ERGO, one of Germany's largest primary insurers, selling property, casualty, health and life cover to households and businesses in Germany and abroad. The group also runs specialty units such as the Hartford Steam Boiler engineering insurer in the US. In the US, the shares trade as MURGY, an unsponsored ADR on the OTC market, where each ADR represents a fraction of one Frankfurt-listed share, so per-ADR prices and dividends are much smaller than the home-share figures quoted in euros.

Full MURGY guide

What does Reinsurance Group of America (RGA) do?

RGA began as the reinsurance arm of General American Life, went public in 1993, and became fully independent when MetLife split off its majority stake in 2008. The company sells reinsurance to life and health insurers, which means it takes a share of claims risk that a primary carrier has already written. Reporting runs through four geographic segments, U.S. and Latin America, Canada, Europe Middle East and Africa, and Asia Pacific, and each one is split into two very different businesses. Traditional reinsurance covers individual and group life and health mortality and morbidity, usually on yearly renewable term treaties that generate steady premium for decades once written. Financial Solutions is the balance-sheet business: asset-intensive annuity and legacy life blocks, longevity swaps, pension risk transfer and capital-relief structures, where RGA takes on reserves and the assets backing them and earns an investment spread. Scale is substantial. Net premiums were $4.472 billion in the second quarter of 2026 and $9.067 billion for the first half, total assets stood at ~$167 billion at June 30, 2026, and the invested portfolio behind those liabilities is ~$145 billion. In fiscal 2025, U.S. and Latin America contributed roughly half of segment revenue, with Asia Pacific next at ~$5.1 billion.

Full RGA guide

MURGY vs RGA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • MURGY drivers: Reinsurance pricing discipline in a softening market; Capital return under Ambition 2030.
  • RGA drivers: Financial Solutions and the Equitable block; Reinvestment spread on a $145 billion portfolio.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The largest single risk is natural catastrophe losses. For RGA, the clearest risk is the one the business exists to take.

MURGY or RGA: which should you pick?

If the story you believe is MURGY's (Reinsurance pricing discipline in a softening market), MURGY is the more direct way to own it; if it is RGA's (Financial Solutions and the Equitable block), RGA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MURGY and RGA guides.

MURGY vs RGA: the full fundamentals

MURGY. Munich Re trades at roughly ~10 times trailing earnings and ~11 times forward estimates as of November 20, 2026, a discount to the broad US market and broadly in line with Swiss Re and Hannover Re. Trailing profit of ~€6.6bn benefited from light major losses in the first half, and the raised ~€6.6bn full-year target implies a modest fourth quarter. For MURGY, per-ADR prices and dividends are a fraction of the home-share figures and move with the euro to dollar rate, so company-level metrics are the cleaner comparison.

RGA. A trailing P/E near 10 and ~1.5x book excluding AOCI on a 19% adjusted operating ROE still reflects a discount for how the returns were earned, even after the shares rallied ~46% over a year. Investors have seen life reinsurers report strong mortality quarters and then take reserve charges, and the asset-intensive growth of the past three years adds credit exposure that only reveals itself in a downturn. The forward multiple below the trailing one, and 2027 consensus EPS of about $30.74 sitting slightly under the ~$31.70 expected for 2026, show the market expecting some normalization from this year's print rather than continued acceleration.

Headline figures (approximate, November 2026): MURGY shows insurance revenue (2026 guide) ~€62bn, revenue (ttm) ~€63bn; up ~12% YoY in the latest quarter, net result (ttm / 9m 2026) ~€6.6bn / ~€5.7bn, q3 2026 net result ~€1.74bn (consensus ~€1.48bn; ~€2.00bn a year earlier); RGA shows revenue (ttm) ~$27.3 billion for the twelve months to September 30, 2026, with third-quarter revenue of ~$7.55 billion up ~21.7% year over year, versus $23.70 billion in fiscal 2025, $22.11 billion in 2024 and $18.57 billion in 2023. The line combines net premiums with net investment income and fee income, so growth reflects both new reinsurance treaties (including over $800 million of U.S. pension risk transfer premium in Q3) and the yield earned on assets backing reserves, not unit sales. Reported in U.S. dollars, with material Canadian dollar, sterling, euro and yen exposure translated in., earnings (ttm) ~$1.71 billion of net income and ~$25.82 of diluted EPS for the twelve months to September 30, 2026, against $1.18 billion and $17.69 in fiscal 2025 and $717 million and $10.73 in 2024. Third quarter 2026 net income was ~$456 million, and pre-tax adjusted operating income was $736 million, or $8.49 of adjusted operating EPS after a 24.1% tax rate. Adjusted EPS has beaten consensus for four straight quarters: $7.75 vs ~$5.75 in Q4 2025, $6.97 vs ~$6.01 in Q1 2026, $8.89 vs ~$6.49 in Q2 2026 and $8.49 vs ~$6.95 in Q3 2026. Consensus for Q4 2026 is ~$7.30., premiums and segment income (q2 2026) Net premiums of $4.472 billion in the quarter and $9.067 billion through the first half, up 11.0% on a reported basis and 9.3% in constant currency excluding pension risk transfer (through September, total premiums excluding PRT were up 8.9%). Pre-tax adjusted operating income by segment in Q2: U.S. and Latin America Traditional $165 million and Financial Solutions $154 million, Asia Pacific Traditional $129 million and Financial Solutions $120 million, EMEA Traditional $39 million and Financial Solutions $133 million, Canada Traditional $38 million and Financial Solutions $18 million, with a $35 million loss in Corporate and Other. Segment reporting simplifies to four segments from Q4 2026., returns and book value Trailing twelve-month adjusted operating ROE of 19.1% excluding AOCI and notable items at September 30, 2026, up from 18.4% at June 30 and above the 13% to 15% intermediate-term target. Book value per share excluding AOCI and the B36 funds-withheld embedded derivative effect was $178.59, compounding at 10.2% a year since the start of 2021 (it was $174.11 at June 30, when book value including AOCI was $209.73)..

The bottom line: MURGY vs RGA

MURGY and RGA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined MURGY and RGA exposure against your real portfolio. It is not an investment adviser.

Wondering how MURGY or RGA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Munich Re

Ask Walnut's AI anything about MURGY and see how it fits what you own.

FAQ

What is the difference between MURGY and RGA?

+

Munchener Ruckversicherungs-Gesellschaft, known as Munich Re, is a Munich-based insurance group founded in 1880. RGA began as the reinsurance arm of General American Life, went public in 1993, and became fully independent when MetLife split off its majority stake in 2008. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is MURGY or RGA the better stock?

+

Neither is universally better. MURGY is the larger incumbent; RGA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, MURGY or RGA?

+

On forward P/E (as of November 2026), MURGY trades at 11.03x and RGA at 8.77x, so RGA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both MURGY and RGA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of MURGY vs RGA?

+

MURGY: The largest single risk is natural catastrophe losses. A major US hurricane, a California earthquake or a run of severe convective storms can cost Munich Re several billion euros in a single quarter; the 2024 Los Angeles wildfires and recurring hurricane seasons show how quickly a light-loss year can turn. Climate change is widening the distribution of outcomes and making historical models less reliable. Second, the reinsurance cycle is turning, and analyst estimates point to 2027 EPS roughly flat with 2026: falling risk-adjusted prices and abundant alternative capital could compress margins faster than cost cuts or volume discipline can offset. Third, reserve risk in long-tail US casualty lines remains an industry-wide concern, as social inflation (larger jury awards and litigation funding) has forced several peers to strengthen reserves for older years. Fourth, MURGY holders carry currency exposure: results and dividends are in euros, so a stronger dollar lowers the dollar value of both, and German withholding tax on dividends applies. Fifth, MURGY is an unsponsored OTC ADR, so liquidity is thinner, spreads can be wider and depositary fees may be deducted from dividends. Finally, a sharp fall in bond yields or a credit event in the investment portfolio would hit earnings and capital. RGA: The clearest risk is the one the business exists to take. Mortality and morbidity experience can move against a book of treaties written years earlier, as it did in 2020 and 2021 when pandemic claims pushed RGA to losses, and the same sensitivity now runs in both directions because longevity exposure in pension risk transfer and annuity blocks pays off when people die earlier than assumed. A single large block priced on wrong assumptions is difficult to unwind. Credit risk has grown alongside the asset-intensive strategy: a ~$145 billion portfolio backing long-dated liabilities carries corporate credit, commercial mortgage and private-asset exposure, and a downgrade cycle would hit capital before it hit income. Accounting adds noise that is easy to mistake for economics. Embedded derivatives on funds-withheld treaties and other adjustments put a $1.88 per share gap between second quarter net income of $7.01 and adjusted operating income of $8.89, and book value per share swings with AOCI, which stood at $209.73 including AOCI versus $173.77 excluding it at June 30, 2026. Management flagged ~$0.83 per share of one-time items in the quarter that it says are not indicative of trend, so extrapolating the record print overstates the base. Competition for asset-intensive blocks comes from private-equity-backed platforms with cheaper capital, which compresses returns on exactly the deals driving growth. Regulatory and tax changes matter more than for most financials: potential Hong Kong tax law changes were called out for Asia Pacific, and Bermuda and U.S. capital rules shape how blocks are structured. After a ~46% one-year gain, the shares also carry less valuation cushion than they did, and consensus for 2027 EPS (~$30.74) sits about 3% below 2026 (~$31.70), so a quarter that falls short of the elevated run rate could weigh on the multiple. Ratings are load-bearing, since cedents choose reinsurers partly on financial strength. Third-quarter results again included favorable items: claims, variable investment income, in-force actions and other items together ran $117 million better than expectations. With ~$5.3 billion of debt and only ~65 million shares outstanding, both leverage and per-share results amplify whatever happens underneath.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MURGY or RGA; figures are approximate and dated (as of November 2026). Verify current data before investing.